Citations (40)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Di You, Lan Zhong, Rutie Yin & Liang Song. (2023) Increase in serum creatinine levels after PARP inhibitor treatment. Journal of Obstetrics and Gynaecology 43:1.
Read now
Read now
Brian W Labadie, David S Morris, Alan H Bryce, Robert Given, Jingsong Zhang, Wassim Abida, Simon Chowdhury & Akash Patnaik. (2022) Guidelines for Management of Treatment-Emergent Adverse Events During Rucaparib Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer. Cancer Management and Research 14, pages 673-686.
Read now
Read now
Siva Nageswara Rao Gajula, Gangireddy Navitha Reddy, Dannarm Srinivas Reddy & Rajesh Sonti. (2020) Pharmacokinetic Drug–Drug Interactions: An Insight into Recent Us Fda-Approved Drugs for Prostate Cancer. Bioanalysis 12:22, pages 1647-1664.
Read now
Read now
Graziela Z Dal Molin, Shannon N Westin & Robert L Coleman. (2018) Rucaparib in Ovarian Cancer: Extending the Use of PARP Inhibitors in the Recurrent Disease. Future Oncology 14:30, pages 3101-3110.
Read now
Read now
Articles from other publishers (36)
Yoshifumi Takahashi, Masahiro Taguchi, Kohei Tamura, Miki Shinohara, Takahiro Koyanagi, Suzuyo Takahashi, Akiyo Taneichi, Yuji Takei, Yasushi Saga & Hiroyuki Fujiwara. (2023) Increase in creatinine levels associated with niraparib maintenance therapy in ovarian cancer. Journal of Obstetrics and Gynaecology Research 50:3, pages 501-507.
Crossref
Crossref
Marylise Sterlé, Alicja Puszkiel, Chloé Burlot, Eva Pereira, Audrey Bellesoeur, Sixtine De Percin, Guillaume Beinse, Jean-David Fumet, Laure Favier, Julie Niogret, Benoit Blanchet, Bernard Royer, Leïla Bengrine-Lefevre & Antonin Schmitt. (2024) Improving olaparib exposure to optimize adverse effects management. Therapeutic Advances in Medical Oncology 16.
Crossref
Crossref
Joanna Stanisławiak-Rudowicz, Agnieszka Karbownik, Danuta Szkutnik-Fiedler, Filip Otto, Tomasz Grabowski, Anna Wolc, Edmund Grześkowiak & Edyta Szałek. (2023) Bidirectional pharmacokinetic drug interactions between olaparib and metformin. Cancer Chemotherapy and Pharmacology 93:1, pages 79-88.
Crossref
Crossref
Feng Deng, Johanna Sistonen, Mikko Neuvonen & Mikko Niemi. (2023) Inhibition of efflux transporters by poly ADP‐ribose polymerase inhibitors. Basic & Clinical Pharmacology & Toxicology 133:4, pages 428-436.
Crossref
Crossref
Dongmei Gao, Guopeng Wang, Honghai Wu & Jiawei Ren. (2023) Physiologically-based pharmacokinetic modeling for optimal dosage prediction of olaparib when co-administered with CYP3A4 modulators and in patients with hepatic/renal impairment. Scientific Reports 13:1.
Crossref
Crossref
Tomohisa Nakada, Toshiyuki Kudo & Kiyomi Ito. (2023) Quantitative Consideration of Clinical Increases in Serum Creatinine Caused by Renal Transporter Inhibition. Drug Metabolism and Disposition 51:9, pages 1114-1126.
Crossref
Crossref
Wassim Abida, David Campbell, Akash Patnaik, Alan H. Bryce, Jeremy Shapiro, Richard M. Bambury, Jingsong Zhang, John M. Burke, Daniel Castellano, Albert Font, Vinod Ganju, Anne-Claire Hardy-Bessard, Ray McDermott, Brieuc Sautois, Dominique Spaeth, Eric Voog, Josep M. Piulats, Elias Pintus, Charles J. Ryan, Axel S. Merseburger, Gedske Daugaard, Axel Heidenreich, Karim Fizazi, Andrea Loehr, Darrin Despain, Andrew D. Simmons, Melanie Dowson, Jowell Go, Simon P. Watkins & Simon Chowdhury. (2023) Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study. European Urology 84:3, pages 321-330.
Crossref
Crossref
Michael Friedlander, Yeh Chen Lee & William P. Tew. (2023) Managing Adverse Effects Associated With Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer: A Synthesis of Clinical Trial and Real-World Data. American Society of Clinical Oncology Educational Book:43.
Crossref
Crossref
Rebecca S. Kristeleit, Yvette Drew, Amit M. Oza, Susan M. Domchek, Susana Banerjee, Rosalind M. Glasspool, Judith Balmaña, Lee-may Chen, Manish R. Patel, Howard A. Burris, Tamar Safra, Jennifer Borrow, Kevin K. Lin, Sandra Goble, Lara Maloney & Ronnie Shapira-Frommer. (2022) Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10. British Journal of Cancer 128:2, pages 255-265.
Crossref
Crossref
Maaike A. C. Bruin, Gabe S. Sonke, Jos H. Beijnen & Alwin D. R. Huitema. (2022) Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology. Clinical Pharmacokinetics 61:12, pages 1649-1675.
Crossref
Crossref
Paloma Orozco Scott, Priya Deshpande & Matthew Abramson. (2022) Genitourinary Cancer: Updates on Treatments and Their Impact on the Kidney. Seminars in Nephrology 42:6, pages 151344.
Crossref
Crossref
André Fedier, Nadia Maggi, Alessandra Tozzi, Muriel Disler, Ricardo Coelho, Francis Jacob & Viola Heinzelmann‑schwarz. (2022) Exposure to escalating olaparib does not induce acquired resistance to PARPi and to other chemotherapeutic compounds in ovarian cancer cell lines. International Journal of Oncology 61:1.
Crossref
Crossref
Yoo-Kyung Song, Min-Ju Kim, Min-Soo Kim, Ji Hun Lee, Suk-Jae Chung, Jin Sook Song, Yoon-Jee Chae & Kyeong-Ryoon Lee. (2022) Role of the efflux transporters Abcb1 and Abcg2 in the brain distribution of olaparib in mice. European Journal of Pharmaceutical Sciences 173, pages 106177.
Crossref
Crossref
Ilya G. Glezerman & Victoria Gutgarts. (2022) Acute Kidney Injury in Cancer Patients. Nephrology Self-Assessment Program 21:1, pages 100-107.
Crossref
Crossref
Xiaojiang Tian, Lin Chen, Di Gai, Sijie He, Xuan Jiang & Ni Zhang. (2022) Adverse Event Profiles of PARP Inhibitors: Analysis of Spontaneous Reports Submitted to FAERS. Frontiers in Pharmacology 13.
Crossref
Crossref
Diego Teyssonneau, Antoine Thiery-Vuillemin, Charles Dariane, Eric Barret, Jean-Baptiste Beauval, Laurent Brureau, Gilles Créhange, Gaëlle Fiard, Gaëlle Fromont, Mathieu Gauthé, Alain Ruffion, Raphaële Renard-Penna, Romain Mathieu, Paul Sargos, Morgan Rouprêt, Guillaume Ploussard & Guilhem Roubaud. (2022) PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers. Journal of Clinical Medicine 11:6, pages 1734.
Crossref
Crossref
Daranjit Sandhu, Albert A. Antolin, Anthony R. Cox & Alan M. Jones. (2021) Identification of different side effects between PARP inhibitors and their polypharmacological multi‐target rationale. British Journal of Clinical Pharmacology 88:2, pages 742-752.
Crossref
Crossref
Diego Teyssonneau, Henri Margot, Mathilde Cabart, Mylène Anonnay, Paul Sargos, Nam-Son Vuong, Isabelle Soubeyran, Nicolas Sevenet & Guilhem Roubaud. (2021) Prostate cancer and PARP inhibitors: progress and challenges. Journal of Hematology & Oncology 14:1.
Crossref
Crossref
Veena S John, Nagashree Seetharamu & Azzour D Hazzan. (2020) Renal insufficiency in patients on PARP inhibitors: Case-based review of possible mechanisms and management. Journal of Onco-Nephrology 5:1, pages 8-12.
Crossref
Crossref
M. A. C. Bruin, C. M. Korse, B. van Wijnen, V. M. T. de Jong, S. C. Linn, B. van Triest, H. Rosing, J. H. Beijnen, D. van den Broek & A. D. R. Huitema. (2020) A real or apparent decrease in glomerular filtration rate in patients using olaparib?. European Journal of Clinical Pharmacology 77:2, pages 179-188.
Crossref
Crossref
Hélène Lazareth, Nicolas Delanoy, Raphaël Cohen, Emilie Boissier, Hamza Ayari, Pierre Combe, Céline Crespel, Elise Mercadier-Riaz, Alexandre Karras, Marie Courbebaisse, Eric Thervet & Nicolas Pallet. (2020) Nephrotoxicity Associated With Niraparib. American Journal of Kidney Diseases 76:6, pages 898-900.
Crossref
Crossref
Wassim Abida, Akash Patnaik, David Campbell, Jeremy Shapiro, Alan H. Bryce, Ray McDermott, Brieuc Sautois, Nicholas J. Vogelzang, Richard M. Bambury, Eric Voog, Jingsong Zhang, Josep M. Piulats, Charles J. Ryan, Axel S. Merseburger, Gedske Daugaard, Axel Heidenreich, Karim Fizazi, Celestia S. Higano, Laurence E. Krieger, Cora N. Sternberg, Simon P. Watkins, Darrin Despain, Andrew D. Simmons, Andrea Loehr, Melanie Dowson, Tony Golsorkhi & Simon Chowdhury. (2020)
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a
BRCA1
or
BRCA2
Gene Alteration
. Journal of Clinical Oncology 38:32, pages 3763-3772.
Crossref
Crossref
Domenica Lorusso, Jesús García-Donas, Jalid Sehouli & Florence Joly. (2020) Management of Adverse Events During Rucaparib Treatment for Relapsed Ovarian Cancer: A Review of Published Studies and Practical Guidance. Targeted Oncology 15:3, pages 391-406.
Crossref
Crossref
Kianoush Kashani, Mitchell H. Rosner & Marlies Ostermann. (2020) Creatinine: From physiology to clinical application. European Journal of Internal Medicine 72, pages 9-14.
Crossref
Crossref
Yvette Drew, Rebecca S. Kristeleit, Ana Oaknin, Isabelle Ray-Coquard, Noor Md. Haris & Elizabeth M. Swisher. (2020) Real-World Delivery of Rucaparib to Patients with Ovarian Cancer: Recommendations Based on an Integrated Safety Analysis of ARIEL2 and Study 10. The Oncologist 25:1, pages e109-e119.
Crossref
Crossref
Laura Tookman, Jonathan Krell, Baleseng Nkolobe, Laura Burley & Iain A. McNeish. (2020) Practical guidance for the management of side effects during rucaparib therapy in a multidisciplinary UK setting. Therapeutic Advances in Medical Oncology 12, pages 175883592092198.
Crossref
Crossref
Christopher Ruark. 2020. Physiologically Based Pharmacokinetic (PBPK) Modeling. Physiologically Based Pharmacokinetic (PBPK) Modeling
139
160
.
Leonard J. Appleman, Jan H. Beumer, Yixing Jiang, Yan Lin, Fei Ding, Shannon Puhalla, Leigh Swartz, Taofeek K. Owonikoko, R. Donald Harvey, Ronald Stoller, Daniel P. Petro, Hussein A. Tawbi, Athanassios Argiris, Sandra Strychor, Marie Pouquet, Brian Kiesel, Alice P. Chen, David Gandara, Chandra P. Belani, Edward Chu & Suresh S. Ramalingam. (2019) Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies. Cancer Chemotherapy and Pharmacology 84:6, pages 1289-1301.
Crossref
Crossref
Peng Yuan, Jianzhong Shentu, Jianming Xu, Wendy Burke, Kate Hsu, Maria Learoyd, Min Zhu & Binghe Xu. (2019) Pharmacokinetics and safety of olaparib tablets as monotherapy and in combination with paclitaxel: results of a Phase I study in Chinese patients with advanced solid tumours. Cancer Chemotherapy and Pharmacology 83:5, pages 963-974.
Crossref
Crossref
Robert L Coleman & Jonathan A Ledermann. (2019) Maintenance Treatment for Recurrent Ovarian Carcinoma – Evidence Supporting the Efficacy and Safety of PARP Inhibitors. European Oncology & Haematology 15:1, pages 29.
Crossref
Crossref
Yoo-Kyung Song, Ji Eun Park, Yunseok Oh, Sungwoo Hyung, Yoo-Seong Jeong, Min-Soo Kim, Wooin Lee & Suk-Jae Chung. (2019) Suppression of Canine ATP Binding Cassette ABCB1 in Madin-Darby Canine Kidney Type II Cells Unmasks Human ABCG2-Mediated Efflux of Olaparib. Journal of Pharmacology and Experimental Therapeutics 368:1, pages 79-87.
Crossref
Crossref
Kaiming Sun, Keith Mikule, Zebin Wang, Grace Poon, Aparajitha Vaidyanathan, Gillian Smith, Zhi-Yi Zhang, Jeffrey Hanke, Sridhar Ramaswamy & Jing Wang. (2018) A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models. Oncotarget 9:98, pages 37080-37096.
Crossref
Crossref
Young-A Heo & Sohita Dhillon. (2018) Olaparib Tablet: A Review in Ovarian Cancer Maintenance Therapy. Targeted Oncology 13:6, pages 801-808.
Crossref
Crossref
Angela Musella, Erlisa Bardhi, Claudia Marchetti, Laura Vertechy, Giusy Santangelo, Carolina Sassu, Federica Tomao, Francesco Rech, Renzo D'Amelio, Marco Monti, Innocenza Palaia, Ludovico Muzii & Pierluigi Benedetti Panici. (2018) Rucaparib: An emerging parp inhibitor for treatment of recurrent ovarian cancer. Cancer Treatment Reviews 66, pages 7-14.
Crossref
Crossref
Robert L Coleman, Amit M Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Andrew Dean, Nicoletta Colombo, Johanne I Weberpals, Andrew Clamp, Giovanni Scambia, Alexandra Leary, Robert W Holloway, Margarita Amenedo Gancedo, Peter C Fong, Jeffrey C Goh, David M O'Malley, Deborah K Armstrong, Jesus Garcia-Donas, Elizabeth M Swisher, Anne Floquet, Gottfried E Konecny, Iain A McNeish, Clare L Scott, Terri Cameron, Lara Maloney, Jeff Isaacson, Sandra Goble, Caroline Grace, Thomas C Harding, Mitch Raponi, James Sun, Kevin K Lin, Heidi Giordano, Jonathan A Ledermann, M Buck, A Dean, M L Friedlander, J C Goh, P Harnett, G Kichenadasse, C L Scott, H Denys, L Dirix, I Vergote, L Elit, P Ghatage, A M Oza, M Plante, D Provencher, J I Weberpals, S Welch, A Floquet, L Gladieff, F Joly, A Leary, A Lortholary, J Lotz, J Medioni, O Tredan, B You, A El-Balat, C Hänle, P Krabisch, T Neunhöffer, M Pölcher, P Wimberger, A Amit, S Kovel, M Leviov, T Safra, R Shapira-Frommer, S Stemmer, A Bologna, N Colombo, D Lorusso, S Pignata, R F Sabbatini, G Scambia, S Tamberi, C Zamagni, P C Fong, A O'Donnell, M Amenedo Gancedo, A Casado Herraez, J Garcia-Donas, E M Guerra, A Oaknin, I Palacio, I Romero, A Sanchez, S N Banerjee, A Clamp, Y Drew, H G Gabra, D Jackson, J A Ledermann, I A McNeish, C Parkinson, M Powell, C Aghajanian, D K Armstrong, M J Birrer, M K Buss, S K Chambers, L-m Chen, R L Coleman, R W Holloway, G E Konecny, L Ma, M A Morgan, R T Morris, D G Mutch, D M O'Malley, B M Slomovitz, E M Swisher, T Vanderkwaak & M Vulfovich. (2017) Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet 390:10106, pages 1949-1961.
Crossref
Crossref
Anton Ivanyuk, Françoise Livio, Jérôme Biollaz & Thierry Buclin. (2017) Renal Drug Transporters and Drug Interactions. Clinical Pharmacokinetics 56:8, pages 825-892.
Crossref
Crossref